Fidelity Investments’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $724M | Sell |
1,457,158
-563,107
| -28% | -$250M | 0.03% | 426 |
|
|
2026
Q1 | $902M | Sell |
2,020,265
-192,331
| -9% | -$89.7M | 0.05% | 322 |
|
|
2025
Q4 | $1B | Sell |
2,212,596
-1,091,172
| -33% | -$470M | 0.05% | 301 |
|
|
2025
Q3 | $1.29B | Sell |
3,303,768
-3,102,604
| -48% | -$1.3B | 0.07% | 230 |
|
|
2025
Q2 | $2.85B | Sell |
6,406,372
-1,320,812
| -17% | -$609M | 0.16% | 94 |
|
|
2025
Q1 | $3.75B | Sell |
7,727,184
-1,491,862
| -16% | -$695M | 0.24% | 59 |
|
|
2024
Q4 | $3.71B | Sell |
9,219,046
-1,305,967
| -12% | -$605M | 0.22% | 61 |
|
|
2024
Q3 | $4.89B | Sell |
10,525,013
-204,415
| -2% | -$98.2M | 0.3% | 45 |
|
|
2024
Q2 | $5.03B | Buy |
10,729,428
+55,908
| +0.5% | +$24.3M | 0.32% | 40 |
|
|
2024
Q1 | $4.46B | Sell |
10,673,520
-2,305,991
| -18% | -$975M | 0.3% | 45 |
|
|
2023
Q4 | $5.28B | Sell |
12,979,511
-1,380,926
| -10% | -$510M | 0.41% | 33 |
|
|
2023
Q3 | $4.99B | Sell |
14,360,437
-268,229
| -2% | -$93.8M | 0.43% | 34 |
|
|
2023
Q2 | $5.15B | Sell |
14,628,666
-1,647,189
| -10% | -$555M | 0.43% | 31 |
|
|
2023
Q1 | $5.13B | Sell |
16,275,855
-1,590,436
| -9% | -$477M | 0.47% | 28 |
|
|
2022
Q4 | $5.16B | Buy |
17,866,291
+500,268
| +3% | +$152M | 0.51% | 25 |
|
|
2022
Q3 | $5.03B | Buy |
17,366,023
+613,012
| +4% | +$176M | 0.52% | 24 |
|
|
2022
Q2 | $4.72B | Buy |
16,753,011
+3,571,298
| +27% | +$956M | 0.47% | 28 |
|
|
2022
Q1 | $3.44B | Buy |
13,181,713
+4,087,860
| +45% | +$970M | 0.27% | 52 |
|
|
2021
Q4 | $2B | Buy |
9,093,853
+4,216,754
| +86% | +$820M | 0.15% | 113 |
|
|
2021
Q3 | $885M | Sell |
4,877,099
-956,964
| -16% | -$187M | 0.07% | 258 |
|
|
2021
Q2 | $1.18B | Sell |
5,834,063
-4,337,179
| -43% | -$907M | 0.09% | 196 |
|
|
2021
Q1 | $2.19B | Sell |
10,171,242
-2,972,684
| -23% | -$653M | 0.19% | 94 |
|
|
2020
Q4 | $3.11B | Sell |
13,143,926
-6,995,070
| -35% | -$1.6B | 0.28% | 55 |
|
|
2020
Q3 | $5.48B | Buy |
20,138,996
+868,479
| +5% | +$240M | 0.55% | 24 |
|
|
2020
Q2 | $5.59B | Sell |
19,270,517
-3,386,072
| -15% | -$918M | 0.62% | 20 |
|
|
2020
Q1 | $5.39B | Sell |
22,656,589
-1,204,873
| -5% | -$276M | 0.75% | 15 |
|
|
2019
Q4 | $5.22B | Sell |
23,861,462
-870,552
| -4% | -$176M | 0.58% | 22 |
|
|
2019
Q3 | $4.19B | Buy |
24,732,014
+32,099
| +0.1% | +$5.68M | 0.5% | 26 |
|
|
2019
Q2 | $4.53B | Buy |
24,699,915
+265,756
| +1% | +$46.5M | 0.53% | 23 |
|
|
2019
Q1 | $4.49B | Buy |
24,434,159
+3,951,050
| +19% | +$730M | 0.54% | 25 |
|
|
2018
Q4 | $3.39B | Buy |
20,483,109
+2,411,631
| +13% | +$418M | 0.46% | 31 |
|
|
2018
Q3 | $3.48B | Buy |
18,071,478
+1,714,071
| +10% | +$305M | 0.39% | 33 |
|
|
2018
Q2 | $2.78B | Sell |
16,357,407
-927,665
| -5% | -$144M | 0.32% | 47 |
|
|
2018
Q1 | $2.82B | Buy |
17,285,072
+553,239
| +3% | +$90.4M | 0.33% | 44 |
|
|
2017
Q4 | $2.51B | Buy |
16,731,833
+171,388
| +1% | +$25.4M | 0.29% | 52 |
|
|
2017
Q3 | $2.52B | Sell |
16,560,445
-1,923,268
| -10% | -$289M | 0.3% | 54 |
|
|
2017
Q2 | $2.38B | Sell |
18,483,713
-380,935
| -2% | -$45.9M | 0.3% | 59 |
|
|
2017
Q1 | $2.06B | Sell |
18,864,648
-1,232,140
| -6% | -$108M | 0.26% | 69 |
|
|
2016
Q4 | $1.48B | Sell |
20,096,788
-2,840,955
| -12% | -$231M | 0.2% | 96 |
|
|
2016
Q3 | $2B | Buy |
22,937,743
+710,639
| +3% | +$67.2M | 0.27% | 74 |
|
|
2016
Q2 | $1.91B | Buy |
22,227,104
+7,092,351
| +47% | +$613M | 0.26% | 70 |
|
|
2016
Q1 | $1.2B | Buy |
15,134,753
+125,568
| +0.8% | +$11.4M | 0.17% | 120 |
|
|
2015
Q4 | $1.89B | Sell |
15,009,185
-2,679,916
| -15% | -$324M | 0.25% | 73 |
|
|
2015
Q3 | $1.84B | Buy |
17,689,101
+1,178,706
| +7% | +$151M | 0.26% | 71 |
|
|
2015
Q2 | $2.04B | Buy |
16,510,395
+1,107,622
| +7% | +$140M | 0.26% | 69 |
|
|
2015
Q1 | $1.82B | Buy |
15,402,773
+946,619
| +7% | +$113M | 0.23% | 81 |
|
|
2014
Q4 | $1.72B | Buy |
14,456,154
+435,461
| +3% | +$49M | 0.22% | 94 |
|
|
2014
Q3 | $1.57B | Buy |
14,020,693
+994,150
| +8% | +$94.6M | 0.21% | 99 |
|
|
2014
Q2 | $1.23B | Buy |
13,026,543
+6,417,821
| +97% | +$450M | 0.17% | 126 |
|
|
2014
Q1 | $467M | Buy |
6,608,722
+891,941
| +16% | +$70.6M | 0.06% | 329 |
|
|
2013
Q4 | $425M | Sell |
5,716,781
-3,311,449
| -37% | -$231M | 0.06% | 348 |
|
|
2013
Q3 | $685M | Sell |
9,028,230
-634,412
| -7% | -$50.5M | 0.1% | 221 |
|
|
2013
Q2 | $772M | Buy |
+9,662,642
| New | +$712M | 0.13% | 175 |
|
Other funds holding VRTX
Fidelity Investments's VRTX Position: Q2 2026 in Review
Fidelity Investments reduced its Vertex Pharmaceuticals (VRTX) stake by 28% in Q2 2026, selling an estimated $250M and leaving 1,457,158 shares worth $724M. The position accounts for 0.03% of the portfolio, ranked #426.
Fidelity Investments first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.59B in Q2 2020. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Fidelity Investments held 1,457,158 shares of Vertex Pharmaceuticals worth $724M as of Q2 2026.
- Fidelity Investments sold 563,107 Vertex Pharmaceuticals shares in Q2 2026, an estimated $250M.
- Vertex Pharmaceuticals made up 0.03% of Fidelity Investments's portfolio in Q2 2026, its #426 holding.
- Fidelity Investments first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Fidelity Investments's Vertex Pharmaceuticals position peaked at $5.59B in Q2 2020.
- 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.